

INDOCIN®
(Indomethacin)

Ph: 262301

Absorption and Excretion

INDOCIN is well absorbed after oral administration in all animals, including man. In dogs, monkeys, rats, and man, peak plasma levels after an oral dose occur within 0.5 to 2 hours. The drug present in the plasma of dog and man is virtually all unchanged indomethacin, but a metabolite (probably the glucuronide conjugate) may be present for the first half hour after intravenous injection in the guinea pig.

The route of excretion is related to the species of animal and is independent of the route of administration or size of dose. Nearly all the compound could be recovered in urine and feces. The rabbit eliminates indomethacin almost entirely in the urine, while the dog excretes nearly all the compound in the feces. The rat, guinea pig, monkey, and man eliminate it by both routes. In man, about two-thirds of the drug is excreted in the urine.

In rabbits, rats, guinea pigs, and monkeys, some indomethacin is metabolized by deacylation or demethylation and the metabolites are excreted in the urine as such or as the glucuronide conjugate. In man, however, no evidence of molecular breakdown has been observed, and virtually all of the material excreted in the urine is indomethacin glucuronide.

AVAILABILITY

No. 3316—INDOCIN capsules, 25 mg. each, are opaque blue and white, imprinted with an MSD trademark and potency, and are supplied in bottles of 100.

No. 3317—INDOCIN capsules, 50 mg. each, are opaque blue and white, imprinted with an MSD trademark and potency, and are supplied in bottles of 100.

REFERENCES

- Bliska, P. J., Wolfheim, F. and Williams, R. C., Jr.: Indomethacin: A New Antirheumatic Agent, *Minnesota Med.* 47: 777, July 1964.
- Boland, E. W.: Nonspecific Anti-Inflammatory Agents. Some Notes on Their Practical Application, Especially in Rheumatic Disorders, *California Med.* 100: 145, March 1964.
- Catoggio, P. M., et al.: Indomethacin in Rheumatoid Arthritis: Properties, Side-Effects, Arthritis & Rheumatism 7: 300, June 1964 (in Soc. Proc.).
- Clark, G. M.: Indomethacin in Rheumatoid Arthritis, Arthritis & Rheumatism 7: 300, June 1964 (in Soc. Proc.).
- Datay, K. K., and Pandya, V. N.: The Value of Indomethacin in Rheumatoid Arthritis, *J. Indian M. A.* 42: 166, Feb. 16, 1964.
- Harman, R. E., Melsinger, M. A. P., Davis, G. E., and Kuehl, F. A., Jr.: The Metabolites of Indomethacin, a New Anti-Inflammatory Drug, *J. Pharmacol. & Exper. Therap.* 143: 215, Feb. 1964.
- Hart, F. D., and Boardman, P. L.: Indomethacin: A New Non-Steroid Anti-Inflammatory Agent, *Brit. M. J.* 3: 965, Oct. 19, 1963.
- Hart, F. D., and Boardman, P. L.: Current Therapeutics: Indomethacin, *Practitioner* 192: 828, June 1964.
- Hucker, H. B., Zaechel, A. G., and Cox, S. V.: Studies on the Physiological Disposition of Indomethacin, *Fed. Proc.* 22: 544, March-April 1963.
- Katz, A. M., Pearson, C. M., and Kennedy, J. M.: The Antirheumatic Effects of Indomethacin in Rheumatoid Arthritis and Other Rheumatic Diseases, *Arthritis & Rheumatism* 6: 281, June 1963 (in Soc. Proc.).
- Katz, A. M., Pearson, C. M., and Kennedy, J. M.: A Clinical Trial of Indomethacin in Rheumatoid Arthritis, *Clin. Pharmacol. & Therap.* 6: 25, Jan.-Feb. 1965.
- Kelly, M.: Indomethacin: An Antirheumatic Drug, *Lancet* 2: 474, Aug. 29, 1964 (in Letters to the Editor).
- Kelly, M.: Indomethacin, Remarkable Antirheumatic Drug, *M. J. Australia* 2: 541, Oct. 3, 1964.
- Lövgren, O., and Allander, E.: Side-Effects of Indomethacin, *Brit. M. J.* 1: 118, Jan. 11, 1964 (in Correspondence).
- Norcross, B. M.: Treatment of Connective Tissue Diseases with a New Non-Steroidal Compound (Indomethacin), *Arthritis & Rheumatism* 6: 290, June 1963 (in Soc. Proc.).
- Paul, W. D.: Indomethacin: A New Anti-Inflammatory Agent, *Arthritis & Rheumatism Foundation Med. Information Bull.*, Vol. 4, March 1963.
- Percy, J. S., Stephenson, P., and Thompson, M.: Indomethacin in the Treatment of Rheumatic Diseases, *Ann. Rheumat. Dis.* 23: 226, May 1964.
- Rothermich, N. O.: Indomethacin: A New Pharmacologic Approach to the Management of Rheumatoid Disease, Arthritis & Rheumatism 6: 295, June 1963 (in Soc. Proc.).
- Rothermich, N. O.: Clinical Experiences with Indomethacin in Rheumatic Diseases, Arthritis & Rheumatism 7: 340, June 1964 (in Soc. Proc.); Some Pharmacologic Effects of Indomethacin, *ibid.*
- Smyth, C. J., Amoroso, C., and Velayos, E.: Objective Evaluation of Indomethacin in Rheumatoid Arthritis, Arthritis & Rheumatism 7: 345, June 1964 (in Soc. Proc.).
- Smyth, C. J., and Godfrey, R.: The Treatment of Rheumatoid Spondylitis with Indomethacin, *Arthritis & Rheumatism* 7: 345, June 1964 (in Soc. Proc.).
- Smyth, C. J., Velayos, E. E., and Amoroso, C.: A Method for Measuring Swelling of Hands and Feet: Part II. Influence of New Anti-Inflammatory Drug, Indomethacin, in Acute Gout, *Acta Rheumat. Scandinav.* 2: 306, 1963.
- Smyth, C. J., Velayos, E. E., and Amoroso, C.: Indomethacin in Acute Gout Using a New Method of Evaluating Joint Inflammation, *Arthritis & Rheumatism* 6: 299, June 1963 (in Soc. Proc.).
- Sunshine, A., Laska, E., Melsner, M., and Morgan, S.: Analgesic Studies of Indomethacin as Analyzed by Computer Techniques, *Clin. Pharmacol. & Therap.* 6: 609, Nov.-Dec. 1964.
- Wanka, J., and Dixon, A. St. J.: Treatment of Osteo-Arthritis of the Hip with Indomethacin: A Controlled Clinical Trial, *Ann. Rheumat. Dis.* 23: 288, July 1964.
- Wanka, J., Jones, L. I., Wood, P. H. N., and Dixon, A. St. J.: Indomethacin in Rheumatic Diseases: A Controlled Clinical Trial, *Ann. Rheumat. Dis.* 23: 218, May 1964.
- Winter, C. A., Risley, E. A., and Nuss, G. W.: Anti-Inflammatory and Antipyretic Activities of Indomethacin, 1-(p-Chlorobenzoyl)-5-Methoxy-2-Methylindole-3-Acetic Acid, *Fed. Proc.* 22: 543, March-April 1963; *J. Pharmacol. & Exper. Therap.* 141: 369, September 1963.
- European Rheumatology, 1963: The Fifth European Congress on Rheumatic Diseases, *Canad. J. A. M.* 89: 781, Oct. 19, 1963.



Merck Sharp & Dohme

Division of Merck & Co., Inc.

West Point, Pa.

Effective May 1965

Printed in U.S.A.